Donna Howe

Statistics

Publications

Citations

375

H-Index

Active since

2018

Affiliations

Cambridge University Hospitals NHS Foundation Trust(Current)

University of Birmingham

Mount Vernon Cancer Centre

Cancer Research UK Clinical Trials Unit

University of Cambridge

Donna Howe is an author at Cambridge University Hospitals NHS Foundation Trust specializing in adjuvant therapy trials, chemotherapy, and disease-free survival analysis.

ORCID

Publications per year

2018–2020

Publications

6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial

Helena Earl, Louise Hiller, Anne-Laure Vallier et al. · The Lancet · 2019 · 283 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

PERSEPHONE: 6 versus 12 months (m) of adjuvant trastuzumab in patients (pts) with HER2 positive (+) early breast cancer (EBC): Randomised phase 3 non-inferiority trial with definitive 4-year (yr) disease-free survival (DFS) results.

Helena Earl, Louise Hiller, Anne-Laure Vallier et al. · Journal of Clinical Oncology · 2018 · 70 citations

Medicine, Oncology, Pharmacotherapy +17

Six versus 12 months’ adjuvant trastuzumab in patients with HER2-positive early breast cancer: the PERSEPHONE non-inferiority RCT

Helena Earl, Louise Hiller, Anne-Laure Vallier et al. · Health Technology Assessment · 2020 · 22 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

1–3 of 3